Catalent acquires Promethera subsidiary to further pDNA manufacturing
Will use new facility in Belgium for commercial production of plasmid DNA
Contract development and manufacturing organization Catalent has acquired Promethera Biosciences' cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot facility in Gosselies, Belgium. The site will feature Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and offers the chance to expand Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to supplement the cell and gene therapy pipeline.
The HCTS facility contains a cleanroom infrastructure, process development and quality control laboratories, along with warehouse space, and will be prepared to produce pDNA manufacturing capabilities up to a 500-liter scale. This new facility is located on Catalent’s existing campus in Gosselies, next to the Delphi Genetics building. Since the purchase of MaSTherCell in March 2020, this acquisition marks the third that Catalent has made at this location.
The HCTS acquisition is expected to create more than 200 jobs over the next five years.
In cohesion with the Gosselies plant, Catalent will be providing the same commercial-scale pDNA production capabilities at its Rockville, MD, facility, with the addition of 500-liter scale bioreactor capacity.
